Literature DB >> 26995223

Tracking metastatic breast cancer: the future of biology in biosensors.

Y C Lim1, A P Wiegmans2.   

Abstract

Circulating tumour cells associated with breast cancer (brCTCs) represent cells that have the capability to establish aggressive secondary metastatic tumours. The isolation and characterization of CTCs from blood in a single device is the future of oncology diagnosis and treatment. The methods of enrichment of CTCs have primarily utilized simple biological interactions with bimodal reporting with biased high purity and low numbers or low purity and high background. In this review, we will discuss the advances in microfluidics that has allowed the use of more complex selection criteria and biological methods to identify CTC populations. We will also discuss a potential new method of selection based on the response of the oncogenic DNA repair pathways within brCTCs. This method would allow insight into not only the oncogenic signalling at play but the chemoresistance mechanisms that could guide future therapeutic intervention at any stage of disease progression.

Entities:  

Keywords:  Circulating tumour cells; DNA damage response; EpCAM; Metastatic breast cancer; Microfluidics

Mesh:

Substances:

Year:  2016        PMID: 26995223     DOI: 10.1007/s12032-016-0748-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  56 in total

1.  Portable filter-based microdevice for detection and characterization of circulating tumor cells.

Authors:  Henry K Lin; Siyang Zheng; Anthony J Williams; Marija Balic; Susan Groshen; Howard I Scher; Martin Fleisher; Walter Stadler; Ram H Datar; Yu-Chong Tai; Richard J Cote
Journal:  Clin Cancer Res       Date:  2010-09-28       Impact factor: 12.531

2.  Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.

Authors:  Shu Zhao; Huike Yang; Minghui Zhang; Dekai Zhang; Yupeng Liu; Yan Liu; Ying Song; Xiaosan Zhang; Hongbin Li; Wenjie Ma; Qingyuan Zhang
Journal:  Cell Biochem Biophys       Date:  2013-03       Impact factor: 2.194

3.  Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.

Authors:  Daniel L Adams; Steingrimur Stefansson; Christian Haudenschild; Stuart S Martin; Monica Charpentier; Saranya Chumsri; Massimo Cristofanilli; Cha-Mei Tang; R Katherine Alpaugh
Journal:  Cytometry A       Date:  2014-12-16       Impact factor: 4.355

4.  Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.

Authors:  Nikolaos Xenidis; Michail Ignatiadis; Stella Apostolaki; Maria Perraki; Kostas Kalbakis; Sofia Agelaki; Efstathios N Stathopoulos; Grigorios Chlouverakis; Evi Lianidou; Stylianos Kakolyris; Vassilis Georgoulias; Dimitris Mavroudis
Journal:  J Clin Oncol       Date:  2009-03-30       Impact factor: 44.544

5.  The identification and characterization of breast cancer CTCs competent for brain metastasis.

Authors:  Lixin Zhang; Lon D Ridgway; Michael D Wetzel; Jason Ngo; Wei Yin; Disha Kumar; Jerry C Goodman; Morris D Groves; Dario Marchetti
Journal:  Sci Transl Med       Date:  2013-04-10       Impact factor: 17.956

6.  Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.

Authors:  Joana M Senra; Brian A Telfer; Kim E Cherry; Cian M McCrudden; David G Hirst; Mark J O'Connor; Stephen R Wedge; Ian J Stratford
Journal:  Mol Cancer Ther       Date:  2011-08-08       Impact factor: 6.261

7.  Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques.

Authors:  A E Ring; L Zabaglo; M G Ormerod; I E Smith; M Dowsett
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

8.  DNA damage response factors from diverse pathways, including DNA crosslink repair, mediate alternative end joining.

Authors:  Sean M Howard; Diana A Yanez; Jeremy M Stark
Journal:  PLoS Genet       Date:  2015-01-28       Impact factor: 5.917

9.  Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection.

Authors:  Katherine Sullivan; Kimberly Cramer-Morales; Daniel L McElroy; David A Ostrov; Kimberly Haas; Wayne Childers; Robert Hromas; Tomasz Skorski
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

10.  Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors.

Authors:  Igor Landais; Sanne Hiddingh; Matthew McCarroll; Chao Yang; Aiming Sun; Mitchell S Turker; James P Snyder; Maureen E Hoatlin
Journal:  Mol Cancer       Date:  2009-12-31       Impact factor: 27.401

View more
  2 in total

Review 1.  Circulating Tumor Cells in Breast Cancer Patients: A Balancing Act between Stemness, EMT Features and DNA Damage Responses.

Authors:  Benedikt Heitmeir; Miriam Deniz; Wolfgang Janni; Brigitte Rack; Fabienne Schochter; Lisa Wiesmüller
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

2.  HET0016 decreases lung metastasis from breast cancer in immune-competent mouse model.

Authors:  Thaiz F Borin; Adarsh Shankar; Kartik Angara; Mohammad H Rashid; Meenu Jain; Asm Iskander; Roxan Ara; Iryna Lebedyeva; Hasan Korkaya; Bhagelu R Achyut; Ali S Arbab
Journal:  PLoS One       Date:  2017-06-13       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.